EDISON EQUITY RESEARCH - ALEXZA PHARMACEUTICALS
June 02 2015 - 10:17AM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH: ALEXZA
PHARMACEUTICALS - STILL AWAITING AN INFLECTION POINT IN ADASUVE
GROWTH
Recent Adasuve orders from Alexza’s commercial partners, Teva and
Ferrer, were below company expectations and reflect continued
challenges to increasing sales momentum. Alexza intends to suspend
Adasuve manufacturing in Q315 and may outsource production
afterwards. The company will also need to raise funds by Q415 to
fund operations, including its clinical studies for AZ-002 and
AZ-007.
US-based Alexza Pharmaceuticals develops products for the acute
treatment of CNS disorders using its proprietary Staccato rapid
inhalation drug delivery system. Lead product Adasuve is approved
in the US and EU for acute treatment of agitation in patients with
schizophrenia or bipolar I disorder.
To view our full report, please click here
Click here to view all of Edison Investment
Research’s published reports